🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9110 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:16 UTC
9110
Studies in scope
industry-sponsored, all four open statuses
4947
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 230 Florida 173 Arizona 111 Illinois 110 Georgia 104
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca173 Eli Lilly and Company151 Merck Sharp & Dohme LLC117 AbbVie112 Novartis Pharmaceuticals107 Clear sponsor filter
State
California230 Florida173 Arizona111 Illinois110 Georgia104
All 47 states
Target enrolment
to
173 of 9110 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-12-14
Active, closed
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-11-23
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
California, Colorado, Florida, Georgia, Illinois, Minnesota, Missouri, New York
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-11-07
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Arkansas, California, Colorado, Florida, Indiana, Iowa, Kentucky, Maryland
2023-10-24
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2023-10-05
Active, closed
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
NCT05943106Non-Muscle- Invasive Bladder Cancer
AstraZeneca
Phase 3
100
Arizona, Arkansas, California, Colorado, Florida, Indiana, Kansas, Maryland
2023-08-11
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234Relapsed/Refractory Multiple Myeloma
AstraZeneca
Phase 1/2
232
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-07-20
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
280
Florida, Minnesota, New York
2023-07-11
Active, closed
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180Asthma
AstraZeneca
Phase 3
94
California, Florida, Kentucky, Louisiana, Missouri, New Jersey, New York, Ohio
2023-04-05
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa
2022-12-29
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2022-12-13
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
AstraZeneca
Phase 3
368
Arizona, Arkansas, California, Colorado, Florida, Illinois, Iowa, Kansas
2022-11-10
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
594
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Mississippi
2022-09-15
Active, closed
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
AstraZeneca
Phase 3
607
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Missouri, New York
2022-09-12
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
AstraZeneca
Phase 2
194
California, Florida, Maryland, Tennessee
2022-08-11
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
341
Florida, Hawaii, New Jersey, New York, Tennessee
2022-08-03
Active, closed
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613Erosive Esophagitis
AstraZeneca
Phase 3
53
Alabama, California, Florida, Indiana, Louisiana, New York, Ohio, Wisconsin
2022-07-01
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
AstraZeneca
Phase 3
644
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Michigan
2022-05-16
Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550Non-small Cell Lung Cancer
AstraZeneca
Phase 2
630
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-04-14
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Arizona, California, Florida, Georgia, Kentucky, New Jersey, New York, North Carolina
2022-02-15
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
1,051
California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan
2022-02-07
Active, closed
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)
AstraZeneca
Phase 3
145
Florida, Maryland, Missouri, New York
2021-11-19
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
California, Florida, Georgia, Massachusetts, Michigan, New York, Ohio, Oregon
2021-10-18
Active, closed
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709Muscle Invasive Bladder Cancer
AstraZeneca
Phase 3
712
California, Connecticut, District of Columbia, Florida, Idaho, Illinois, Indiana, Iowa
2021-08-05
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
315
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2021-06-30
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
AstraZeneca
Phase 3
367
Alabama, Arizona, California, Colorado, Florida, Idaho, Michigan, New Jersey
2021-06-08
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kentucky, Maryland
2021-04-26
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
AstraZeneca
Phase 1
226
Florida, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Wisconsin
2021-03-02
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Alabama, Arkansas, California, Colorado, Florida, Indiana, Louisiana, Maryland
2021-01-28
Active, closed
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
NCT04538742Metastatic Breast Cancer
AstraZeneca
Phase 1/2
245
Florida, New York, Ohio, Tennessee, Texas, Virginia
2020-12-28
Active, closed
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction
AstraZeneca
Phase 3
957
California, Florida, Indiana, Kentucky, Massachusetts, New York, Tennessee, Texas
2020-11-17
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
AstraZeneca
Phase 3
185
Florida, Maryland, Michigan, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2020-08-04
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Kansas, Kentucky
2020-07-24
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,012
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Michigan
2020-07-13
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
AstraZeneca
Phase 3
805
Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2020-05-05
Active, closed
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
NCT04214288Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 2
240
Alabama, California, Florida, Nebraska, Ohio, Tennessee, Wisconsin
2020-04-22
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
818
Arizona, California, Florida, Kansas, Maryland, Massachusetts, Minnesota, Missouri
2020-04-16
Active, closed
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300Asthma
AstraZeneca
Phase 4
75
Alabama, California, Florida, Georgia, Indiana, Iowa, Kansas, Michigan
2019-10-08
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
California, Florida, Kansas, Kentucky, Massachusetts, Nevada, New York, Ohio
2019-07-02
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
AstraZeneca
Phase 3
923
California, Florida, Illinois, Kansas, Maryland, Michigan, New York, Ohio
2019-06-25
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Kansas
2019-04-29
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
California, District of Columbia, Florida, Kansas, Kentucky, Massachusetts, Missouri, North Carolina
2019-04-16
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
724
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Georgia, Illinois
2019-03-06
Active, closed
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643Advanced Ovarian Cancer
AstraZeneca
Phase 3
1,407
California, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri
2019-01-04
Active, closed
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
NCT03775486Non-small Cell Lung Cancer NSCLC
AstraZeneca
Phase 2
401
Florida, Missouri, Pennsylvania, Tennessee, Texas
2018-12-21
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
825
Arizona, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2018-12-06
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
AstraZeneca
Phase 3
724
California, District of Columbia, Florida, Hawaii, Illinois, Louisiana, Michigan, Minnesota
2018-11-30
Active, closed
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587ER+ HER2- Advanced Breast Cancer
AstraZeneca
Phase 1
396
Colorado, Florida, Pennsylvania, Tennessee, Utah
2018-10-11
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Alabama, California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Kansas
2018-09-27
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
AstraZeneca
Phase 3
730
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2018-09-27
Active, closed
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
NCT03459846Urinary Bladder Neoplasms
AstraZeneca
Phase 2
154
Alabama, Arizona, Florida, Kentucky, New York, Pennsylvania, Tennessee, Washington
2018-03-16
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,324
California, District of Columbia, Florida, Kansas, Maryland, Michigan, Minnesota, New York
2017-10-11
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
AstraZeneca
Phase 3
1,186
Arizona, California, Florida, Kentucky, Missouri, Ohio, Pennsylvania, Tennessee
2017-06-01
Active, closed
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
NCT02546661Muscle Invasive Bladder Cancer
AstraZeneca
Phase 1
117
California, Connecticut, Florida, New York, Ohio, Tennessee
2016-12-28
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
AstraZeneca
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan
2015-11-02
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca
Phase 3
682
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2015-10-21
Active, closed
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282Non-Small-Cell Lung Carcinoma NSCLC
AstraZeneca
Phase 3
1,118
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Maryland, Minnesota
2015-07-21
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca
Phase 3
510
Colorado, Florida, Georgia, Illinois, Louisiana, Massachusetts, New York, North Carolina
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Alabama, California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
AstraZeneca
Phase 3
450
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2013-08-26
Active, closed
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
NCT01081951Ovarian Cancer
AstraZeneca
Phase 2
162
California, Florida, Indiana, Massachusetts, New York, Oregon
2010-02-04
Active, closed
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
AstraZeneca
Phase 3
736
Arizona, California, Connecticut, Florida, Illinois, Maryland, Michigan, Missouri
2005-02-13
Rows per page Showing 101–173 of 173
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-usa/state/florida?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.